



A



B

RvD1



C

DHA Bioactive Metabolome	Spleen	Bone Marrow
RvD1	1.8 ± 0.6	1.5 ± 0.7
RvD2	0.0 ± 0.0	10.2 ± 2.8 ###
RvD3	0.6 ± 0.1	11.6 ± 2.2 ###
RvD5	1.5 ± 0.7	5.5 ± 1.4 ##
RvD6	2.8 ± 1.9	6.9 ± 4.1
PD1	1.8 ± 1.3	0.7 ± 0.2
10S,17S-diHDHA	2.2 ± 1.2	8.4 ± 4.0
16,17S-diHDHA	3.7 ± 0.7	14.5 ± 5.8 ##
MaR1	0.2 ± 0.1	0.7 ± 0.3
14S,21-diHDHA	0.9 ± 0.3	7.0 ± 2.1 ###
EPA Bioactive Metabolome		
RvE1	0.2 ± 0.2	11.1 ± 4.4 ##
RvE2	0.0 ± 0.0	0.0 ± 0.0
RvE3	5.3 ± 4.4	6.2 ± 2.3
LXA ₅	1.5 ± 0.2	11.2 ± 4.8
LXB ₅	9.6 ± 3.9	4.3 ± 3.1
5,15-diHEPE	0.5 ± 0.2	1.3 ± 0.8
AA Bioactive Metabolome		
LXA ₄	2.9 ± 0.7	32.2 ± 6.5 ###
LXB ₄	49.5 ± 8.1	284.9 ± 30.8 ###
5,15-diHETE	1.4 ± 0.4	11.4 ± 3.9 ##
LTB ₄	34.2 ± 14.4	57.6 ± 14.7
20-OH-LTB ₄	0.4 ± 0.3	4.4 ± 1.7 ##
PGD ₂	12.1 ± 4.6	792.7 ± 153.0 ###
PGE ₂	24.0 ± 9.1	764.3 ± 128.3 ###
PGF _{2α}	5.8 ± 2.7	290.1 ± 44.2 ###
TXB ₂	50.8 ± 20.8	195.4 ± 53.2 ##

D

DHA Bioactive Metabolome	Vehicle	PTH
RvD1	0.8 ± 0.4	6.2 ± 2.2 ###
RvD2	5.3 ± 1.5	23.7 ± 13.7 ##
RvD3	6.0 ± 1.2	22.4 ± 7.4 ###
RvD5	2.8 ± 0.7	3.7 ± 1.1
RvD6	3.6 ± 2.1	6.0 ± 4.3
PD1	0.4 ± 0.1	0.4 ± 0.3
10S,17S-diHDHA	4.4 ± 2.1	7.3 ± 2.6
16,17S-diHDHA	7.5 ± 3.0	8.6 ± 4.3
MaR1	0.4 ± 0.2	0.3 ± 0.4
14S,21-diHDHA	3.6 ± 1.1	6.7 ± 2.9 #
EPA Bioactive Metabolome		
RvE1	5.8 ± 2.3	9.6 ± 2.5
RvE2	0.0 ± 0.0	0.0 ± 0.0
RvE3	3.2 ± 1.2	21.7 ± 8.9 ###
LXA ₅	5.8 ± 2.5	12.5 ± 4.9 #
LXB ₅	2.2 ± 1.6	3.4 ± 2.6
5,15-diHEPE	0.7 ± 0.4	1.8 ± 1.4
AA Bioactive Metabolome		
LXA ₄	16.7 ± 3.4	50.1 ± 13.3 ###
LXB ₄	147.6 ± 16.0	214.0 ± 64.0 #
5,15-diHETE	5.9 ± 2.0	7.9 ± 2.7
LTB ₄	29.8 ± 7.6	27.8 ± 14.8
20-OH-LTB ₄	2.3 ± 0.9	3.7 ± 3.7
PGD ₂	410.6 ± 79.3	448.8 ± 123.6
PGE ₂	395.9 ± 66.5	425.2 ± 95.5
PGF _{2α}	150.3 ± 22.9	154.4 ± 20.8
TXB ₂	101.2 ± 27.6	102.5 ± 26.4

Supplemental Figure 1: Pro-resolving lipid mediator levels are found with their bioactive range in hematopoietic tissues of unchallenged mice:regulation by PTH. Bone marrows and spleens were collected from unchallenged mice (A-C) or (D) from bone marrows after mice were administered vehicle/control (CT) or PTH (50 mg/kg),2h later femurs and tibias collected and snap frozen. Lipid mediator levels were assessed following solid phase extraction by LC-MS-MS based lipid mediator metabololipidomics (see methods for details). (A) Representative MRM traces for the identified lipid mediators in murine self-resolving exudates. (B) Accompanying MS/MS spectra used for identification. (C,D) Individual bioactive lipid mediator and precursor/pathway markers at the where: Q1, M-H (parent ion); and Q3, diagnostic ion in the MS-MS (daughter ion) along with mean ± SEM values for each of the mediators. Results are expressed in pg/1x10⁸ cells. The detection limit was ~ 1 pg. Results for C are mean ± SEM. n= 5 mice; D n= 8-9 mice #p<0.05, ##p<0.01, ###p<0.001 vs bone marrow or Vehicle treated mice lipid mediator profiles.

Supplemental Videos: Video 1) Video of murine bone marrow macrophages (Green BIODIPY label) phagocytosing apoptotic osteoblasts (Cell Tracker orange label) over a 24hr period, and Videos 2-5) 4 videos in 3D movie format of Z stack images from co-incubation of apoptotic osteoblasts (Red CMPTX label) and bone marrow macrophages (Green BIODIPY label) and corresponding to static images in Figure 3B.